Summary
Electrical brain stimulation has been successfully used since the 1990s to treat neurological illnesses, particularly movement disorders.
Most of the devices for this novel approach are based on the old pacemaker technology. Companies are unwilling to take device development risks & rely on established tech, limiting new therapy developments. Many neurological diseases are still treated with pharmaceuticals only, which has limited effectiveness and causes severe side effects. Neuromodulation—electrical stimulation research has increased in recent decades. Additional recording capabilities & closed loop therapy expand therapeutic options.
CorTec aims to provide novel implantable tech to overcome the current limitations: it enables researchers, medical institutions & industry to develop new therapies & devices. We plan to finalise the development of our tech for stroke rehabilitation, conduct clinical trials & get market approval in 2029, generating €250M in sales in 2030.
Most of the devices for this novel approach are based on the old pacemaker technology. Companies are unwilling to take device development risks & rely on established tech, limiting new therapy developments. Many neurological diseases are still treated with pharmaceuticals only, which has limited effectiveness and causes severe side effects. Neuromodulation—electrical stimulation research has increased in recent decades. Additional recording capabilities & closed loop therapy expand therapeutic options.
CorTec aims to provide novel implantable tech to overcome the current limitations: it enables researchers, medical institutions & industry to develop new therapies & devices. We plan to finalise the development of our tech for stroke rehabilitation, conduct clinical trials & get market approval in 2029, generating €250M in sales in 2030.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190118958 |
| Start date: | 01-11-2022 |
| End date: | 31-10-2024 |
| Total budget - Public funding: | 3 675 427,50 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Electrical brain stimulation has been successfully used since the 1990s to treat neurological illnesses, particularly movement disorders.Most of the devices for this novel approach are based on the old pacemaker technology. Companies are unwilling to take device development risks & rely on established tech, limiting new therapy developments. Many neurological diseases are still treated with pharmaceuticals only, which has limited effectiveness and causes severe side effects. Neuromodulation—electrical stimulation research has increased in recent decades. Additional recording capabilities & closed loop therapy expand therapeutic options.
CorTec aims to provide novel implantable tech to overcome the current limitations: it enables researchers, medical institutions & industry to develop new therapies & devices. We plan to finalise the development of our tech for stroke rehabilitation, conduct clinical trials & get market approval in 2029, generating €250M in sales in 2030.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
